

CITATION REPORT

List of articles citing

Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)

DOI: 10.1093/ofid/ofaa130

Open Forum Infectious Diseases, 2020, 7, ofaa130.

Source: <https://exaly.com/paper-pdf/77642535/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
144	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. 2020 , 80, 1929-1946		45
143	Chloroquine against malaria, cancers and viral diseases. 2020 , 25, 2012-2012		23
142	An open-label, randomized trial of the combination of IFN- β plus TFF2 with standard care in the treatment of patients with moderate COVID-19. 2020 , 27, 100547		17
141	A Commentary on "A comparative overview of COVID-19, MERS and SARS: Review article" (International Journal of Surgery 2020; 81:1-8). 2020 , 83, 28-29		
140	Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine. 2020 , 2020, 4582612		9
139	Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. 2020 , 32, 3159-3166		9
138	Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. 2020 , 6, 2304-2318		25
137	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. 2020 , 108, 1135-1149		17
136	Public policy lessons from the Covid-19 outbreak: How to deal with it in the post-pandemic world?. 2020 , 1-14		0
135	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. 2020 , 27, 434-441		2
134	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. 2020 , 29, 100645		34
133	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa500	1	26
132	Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19). <i>Journal of Cardiac Critical Care TSS</i> , 2020 , 4, 121-131	0.3	
131	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. 2020 , 173, 623-631		298
130	SARS-CoV-2 and the Nervous System: From Clinical Features to Molecular Mechanisms. 2020 , 21,		73
129	The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. 2020 , 182, 104902		14
128	COVID-19 and liver disease: An update. 2020 , 43, 472-480		12

127	Is fenofibrate the missing piece in COVID-19 management?. 2020 , 56, 132-133	
126	Hydroxychloroquine Exhibits a Strong Complex Interaction with DNA: Unraveling the Mechanism of Action. 2020 , 11, 9528-9534	7
125	Finding disease modules for cancer and COVID-19 in gene co-expression networks with the Core&Peel method. 2020 , 10, 17628	3
124	Zinc and COVID-19: Basis of Current Clinical Trials. 2021 , 199, 2882-2892	55
123	Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors. 2020 , 19, 4706-4717	9
122	Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19). 2020 , 13, 1023-1033	6
121	Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2. 2020 , 6, 1-9	37
120	Pharmacogenomics of COVID-19 therapies. 2020 , 5, 35	36
119	Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 and SARS-CoV. 2020 , 94,	113
118	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. 2020 , 10, 22139	41
117	COVID-19 and liver disease: An update. 2020 , 43, 472-480	1
116	Hydroxychloroquine is protective to the heart, not harmful: a systematic review. 2020 , 37, 100747	11
115	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. 2020 , 67, 1201-1211	15
114	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. 2020 , 383, 517-525	803
113	An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). 2020 , 40, 591-601	55
112	COVID-19: What you need to know. 2020 , 20, 100756	7
111	COVID-19: from epidemiology to treatment. 2020 , 41, 2092-2112	45
110	An Alert to COVID-19 Literature in Predatory Publishing Venues. 2020 , 46, 102187	22

109	Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2. 2020 , 144, 110046	4
108	SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. 2020 , 9,	29
107	Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. 2020 , 83, 1150-1159	13
106	Geranium and Lemon Essential Oils and Their Active Compounds Downregulate Angiotensin-Converting Enzyme 2 (ACE2), a SARS-CoV-2 Spike Receptor-Binding Domain, in Epithelial Cells. 2020 , 9,	44
105	Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection. 2021 , 538, 156-162	4
104	Chloroquine commonly induces hormetic dose responses. 2021 , 755, 142436	5
103	Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. 2021 , 46, 17-27	14
102	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. 2021 , 41, 1375-1426	11
101	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. 2021 , 384, 417-427	108
100	Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study. 2021 , 27, 611-617	12
99	COVID-19 pandemic: mechanism, diagnosis, and treatment. 2021 , 96, 299-308	9
98	Exploring lectin-glycan interactions to combat COVID-19: Lessons acquired from other enveloped viruses. 2021 , 31, 358-371	15
97	Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States. 2021 , 72, e558-e565	61
96	Review of pharmacologic and immunologic agents in the management of COVID-19. 2021 , 3, 148-155	3
95	Designing a next generation multi-epitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches. 2021 , 11, 47	13
94	Hydroxychloroquine and SARS-CoV-2 (COVID-19): An Old Problem and New Considerations in Ophthalmology. 2021 , 14, 78-81	
93	First principle simulation of coated hydroxychloroquine on Ag, Au and Pt nanoparticles. 2021 , 11, 2131	8
92	Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets. 2021 , 10,	5

91	validation of potent phytochemical orientin as inhibitor of SARS-CoV-2 spike and host cell receptor GRP78 binding. 2021 , 7, e05923	4
90	Pediatric Coronavirus Disease 2019: Clinical Features and Management. 2021 , 58, 453-460	3
89	Antiviral optical techniques as a possible novel approach to COVID-19 treatment. 2021 , 14, 2130002	3
88	Impact of Cardiovascular Diseases on COVID-19: A Systematic Review. 2021 , 27, e930032	2
87	Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. 2021 , 33, 100773	28
86	Virtual Screening and Molecular Design of Potential SARS-COV-2 Inhibitors. 2021 , 76, 95-113	0
85	What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology. 2021 , 13, 175-184	5
84	COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?. 2021 , 13, 259-284	12
83	Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir. 2021 , 7, 792-802	24
82	Coronavirus (COVID-19) pandemic: Outbreak, current scenario and impact on human physiology in Pakistan. 2021 , 012-020	
81	Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. 2021 , 9, E693-E702	7
80	Contrast sensitivity assessment for early detection of hydroxychloroquine toxicity. 2021 , 11206721211010612	
79	Repurposed drug against COVID-19: nanomedicine as an approach for finding new hope in old medicines. 2021 , 2, 022007	2
78	Existing Drugs Considered as Promising in COVID-19 Therapy. 2021 , 22,	9
77	Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?. 2021 , 88, 105143	4
76	SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. 2021 , 35, 109055	70
75	Immuno-Informatics Quest against COVID-19/SARS-COV-2: Determining Putative T-Cell Epitopes for Vaccine Prediction. 2021 , 21, 541-552	12
74	COVID-19-Associated Cardiovascular Complications. 2021 , 9,	12

73	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. 2021 , 47, 867-886	20
72	A review on the pharmacokinetic properties and toxicity considerations for chloroquine and hydroxychloroquine to potentially treat coronavirus patients. 2021 , 1-12	2
71	A Novel Carbon Nitride Nanosheets-based Electrochemical Sensor for Determination of Hydroxychloroquine in Pharmaceutical Formulation and Synthetic Urine Samples. 2021 , 33, 2152	3
70	Mental health in patients with rheumatic diseases related to COVID-19 pandemic: Experience in a tertiary care center in Latin America. 2021 , 30, 1879-1887	1
69	Anticancer Effects of Combination of Indole-3-Carbinol and Hydroxychloroquine on Ehrlich Ascites Carcinoma via Targeting Autophagy and Apoptosis. 2021 , 1-17	1
68	Various theranostics and immunization strategies based on nanotechnology against Covid-19 pandemic: An interdisciplinary view. 2021 , 278, 119580	5
67	Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment of COVID-19. 2021 , 13,	2
66	Computational study for identifying promising therapeutic agents of hydroxychloroquine analogues against SARS-CoV-2. 2021 , 1-15	1
65	Hydroxychloroquine dans les maladies systémiques et auto-immunes : où en sommes-nous?. 2021 , 88, 346-353	
64	Prévalence du COVID-19 chez les patients atteints de rhumatismes inflammatoires chroniques traités par biothérapies ou inhibiteurs des JAK : une étude basée sur la population au cours des deux premiers mois de l'épidémie de COVID-19 en Italie. 2021 , 88, 377-381	
63	Novel pathogens, same old habits. A call for evidence-based research in the fight against COVID-19. 2021 , 51, 632-633	0
62	Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate. 2021 , 44, 102163	2
61	Molecular Docking Study of the Binding Interaction of Hydroxychloroquine, Dexamethasone and Other Anti-Inflammatory Drugs with SARS-CoV-2 Protease and SARS-CoV-2 Spikes Glycoprotein. 2021 , 11, 19-49	0
60	Host Defence RNases as Antiviral Agents against Enveloped Single Stranded RNA Viruses. 2021 , 12, 444-469	10
59	The journey of antimalarial drugs against SARS-CoV-2: Review article. 2021 , 24, 100604	17
58	Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo. 2020 , 94,	1
57	Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. 2020 , 87, 439-443	46
56	In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2. 2021 , 39, 3747-3759	31

55	Treatments in the COVID-19 pandemic: an update on clinical trials. 2020 , 25, 81-88		8
54	Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo.		52
53	Concentration-dependent mortality of chloroquine in overdose.		2
52	Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: Study Protocol for a Pragmatic Randomized Controlled Trial.		1
51	The race to find a SARS-CoV-2 drug can only be won by a few chosen drugs: a systematic review of registers of clinical trials of drugs aimed at preventing or treating COVID-19.		1
50	Simeprevir potently suppresses SARS-CoV-2 replication and synergizes with remdesivir.		13
49	THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19.		2
48	SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. 2020 ,		26
47	Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19. 2020 ,		8
46	COVID-19 Preprints and Their Publishing Rate: An Improved Method.		5
45	COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. 2020 , 68, 1636-1646		21
44	[The fight against COVID-19 in Cameroon [needs a second breath]]. <i>Pan African Medical Journal</i> , 2020 , 37, 14	1.2	2
43	Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. <i>Pan African Medical Journal</i> , 2020 , 37, 9	1.2	8
42	Complexities of diagnosis and management of COVID-19 in autoimmune diseases: Potential benefits and detriments of immunosuppression. <i>World Journal of Clinical Cases</i> , 2020 , 8, 3669-3678	1.6	3
41	An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2020 , 31,	1.6	8
40	Hydroxychloroquine in rheumatic autoimmune disorders and beyond. <i>EMBO Molecular Medicine</i> , 2020 , 12, e12476	12	29
39	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. <i>Infection and Drug Resistance</i> , 2020 , 13, 4673-4695	4.2	20
38	Impact of Chronic Use of Antimalarials on SARS-CoV-2 Infection in Patients With Immune-Mediated Rheumatic Diseases: Protocol for a Multicentric Observational Cohort Study. <i>JMIR Research Protocols</i> , 2020 , 9, e23532	2	4

37	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. <i>Frontiers in Pharmacology</i> , 2020 , 11, 597985	5.6	13
36	Emerging trends from COVID-19 research registered in the Clinical Trials Registry - India. <i>Indian Journal of Medical Research</i> , 2021 , 153, 26-63	2.9	6
35	Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China. <i>BioScience Trends</i> , 2021 , 14, 408-414	9.9	2
34	Concentration-dependent mortality of chloroquine in overdose. <i>ELife</i> , 2020 , 9,	8.9	17
33	Energy dynamics for systemic configurations of virus-host co-evolution.		
32	Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis.		0
31	Coronavirus and Homo Sapiens. <i>Journal of Cardiac Critical Care TSS</i> ,	0.3	
30	NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals. <i>Tanaffos</i> , 2020 , 19, 91-99	0.5	5
29	Does treatment with hydroxychloroquine or chloroquine lead to QTc prolongation in children?. <i>Progress in Pediatric Cardiology</i> , 2021 , 101465	0.4	
28	Deep Learning Algorithms Achieved Satisfactory Predictions When Trained on a Novel Collection of Anticoronavirus Molecules.. <i>Frontiers in Genetics</i> , 2021 , 12, 744170	4.5	1
27	Technical procedures and REDCap tools for internet-based clinical trials.. <i>Contemporary Clinical Trials</i> , 2022 , 106660	2.3	0
26	Outpatient Therapies for COVID-19: How Do We Choose?. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofac008		3
25	Repurposing the drug, ivermectin, in COVID-19: toxicological points of view.. <i>European Journal of Medical Research</i> , 2022 , 27, 21	4.8	1
24	Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.. <i>BMJ Open</i> , 2022 , 12, e051579	3	1
23	Emerging quinoline and quinolone based antibiotics in the light of epidemics.. <i>Chemical Biology and Drug Design</i> , 2022 ,	2.9	1
22	Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa.. <i>IScience</i> , 2022 , 103880	6.1	0
21	Outpatient therapies for COVID-19: How do we choose?.		
20	New Insights into Potential Beneficial Effects of Bioactive Compounds of Bee Products in Boosting Immunity to Fight COVID-19 Pandemic: Focus on Zinc and Polyphenols.. <i>Nutrients</i> , 2022 , 14,	6.7	1

19	A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.. <i>Drug Design, Development and Therapy</i> , 2022 , 16, 685-715	4.4	2
18	Accelerating Drug Discovery and Development. 2022 , 385-420		
17	Neuropsychiatric manifestation of the drugs used in the treatment of SARS-2-CoV-2019 (COVID-19) infection and their management: An overview and practice implications.. <i>Asian Journal of Psychiatry</i> , 2022 , 73, 103101	6.7	1
16	Hydroxychloroquine (HCQ) Exhibits Better Binding to the Main Protease (Mpro) Compared to Spike Protein (S protein) of SARS-CoV-2: An In-silico Analysis. <i>Clinical Cancer Drugs</i> , 2021 , 8, 106-115	0.2	
15	Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates.. <i>Molecules</i> , 2022 , 27,	4.8	3
14	Hydroxychloroquine for COVID19: The curtains close on a comedy of errors.. <i>The Lancet Regional Health Americas</i> , 2022 , 11, 100268		1
13	COVID-19 in G6PD-deficient patients, oxidative stress, and neuropathology.. <i>Current Topics in Medicinal Chemistry</i> , 2022 ,	3	1
12	The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review. <i>Inflammopharmacology</i> ,	5.1	0
11	Clinical update of medications associated with QT prolongation among COVID-19 patients. 1-10		
10	Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19.		
9	A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate using ultra-high-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry and liquid chromatography-solid-phase extraction-nuclear magnetic resonance. 2022 , 36,		
8	The airliquid interface model. 2022 , 51-72		0
7	Misinformation through predatory practices.		0
6	Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. 2022 , 20,		1
5	Viral modulation of lipid rafts and their potential as putative antiviral targets.		0
4	Free radical induced degradation and computational studies of hydroxychloroquine in aqueous solution. 2023 , 110785		0
3	A Comprehensive Perspective of Traditional Arabic or Islamic Medicinal Plants as an Adjuvant Therapy against COVID-19. 2023 , 103561		0
2	Surfing the Waves: Differences in Hospitalised COVID-19 Patients across 4 Variant Waves in a Belgian University Hospital. 2023 , 15, 618		0

- 1 Convex optimization for maximizing the degradation efficiency of chloroquine in a flow-by electrochemical reactor.

o